LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio sat down with new member ProductLife, to find out about their long-term goals Interview with… Xavier Duburcq, CEO at ProductLife Group

01/12/2021
INTERVIEW

Xavier Duburcq

Xavier Duburcq joined ProductLife in May 2020 after 20 years of experience in the Lifesciences space. Xavier is pharmacist as a background, and hold a Ph.D. in Immunology, Xavier was involved in his early career in the development of new medical devices for the detection of hepatitis, HIV, malaria and other blood viruses at Sedac Therapeutics and Biorad. He then spent 13 years at Altran, where he was VP in charge of LiveScience; Xavier led a team that has delivered substantial international development across Europe, Asia and North America. Since his arrival at PLG, the group as triple its size, including significant development in North America and Asia and has developed solid experience in Med Tech and Biotech.

Xavier Duburcq, CEO at ProductLife Group

1) What inspired ProductLife to join EuropaBio?
Europe has a complex biotech landscape: thousands of companies, multiple paths to innovation and financing, and marked differences among countries. Europe’s strength as a global powerhouse for scientific research and publication does not yet translate into new medicines as it should be. From conception and development to approval and launch, each stage of the commercialization process requires individuals with specific expertise, in areas ranging from clinical data collection to capturing and reporting adverse events. With today’s ever-changing laws and regulations, there’s a growing demand for well-rounded professionals who understand the overall regulatory landscape and can help companies effectively bring products to market. Developing that understanding requires staying up-to-date on emerging trends within the industry. PLG will share its expertise at EuropaBio across National Associations Council and the SME platform in order to improve the regulatory ecosystem for increasing European biotech companies’ competitiveness in Europe.

2) How has ProductLife changed over the years as technologies advance?
Since 1993, ProductLife Group (PLG) has made dramatic changes in its philosophy. From a fully European company, we became in a few years’ time a European company with a global footprint. Today, PLG is supporting its clients through the entire life cycle of medicines and MedTech products, combining local expertise with global reach and spanning more than 130 countries. In the specific field of biotech, PLG has set up a team of biopharmaceutical regulatory experts, with an extensive experience and a strong understanding of biopharmaceutical product development, registration, market access and commercialization. PLG is providing flexible and tailored, pre-clinical, clinical and market access solutions designed to notably - but not only - help mid-size and small biopharmaceutical companies move forward in their effort to get treatments to patients – from helping to define the development plan, to implementation of all stages of product development, through launch and commercialization – in order to deliver compelling results to regulatory authorities, investors, and stakeholders.

3) What are your plans for expansion?
First of all, PLG will pursue its international expansion. On a regulatory stand-point, there is an increasing demand for the faster approval process, changing regulatory landscape, growth in emerging fields, such as specialty therapies, new vaccines, orphan drugs, and personalized medicines. At PLG, we will continue to assist our customers : 1) to file the important gap in translational research, 2) to accelerate the development of regulatory sciences that reflect the new integrated approaches to R&D and healthcare delivery that are transforming healthcare, 3) to create new businesses placing our customers at the forefront of cross-sectorial benefits for patients, and 4) to increase partnerships worldwide in order to operate in an efficient and flexible way.

4) How do you see ProductLife being able to transform the regulatory and pharmacovigilance services?
Biopharmaceutical companies are actively involved in the development of innovative molecules that fulfil the unmet needs of patients. The biopharmaceutical market is anticipated to witness substantial growth in the future. For biopharma innovators with so much opportunity ahead of them, there is a lot to think about. Considerations must include strategies for product development, and the need to fulfil regulatory obligations at all stages of development as well as pre- and post-market. To maximise their potential, these companies must ensure they are targeting the right markets with the right medicines, that they have access to the scale of funding they need at the right stages, and that they are able to safely fast-track delivery of much-needed treatments at an affordable and sustainable price point, harnessing the right partnerships as they go. In order to reach this goal, Real world data that better supports scientific or commercial analysis. as well as Digital health (AI) will be more and more integrated into new medicine development at PLG.

Interview with ProductLife


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

Health Biomanufacturing: Feedstock for Preparedness and Resilience


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.